We use cookies for a better user experience. Read our Privacy Policy

I Agree

Anti-radiation Drugs Market

Anti-radiation Drugs Market (Compound: Potassium Iodide, Prussian Blue, DTPA, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Global Anti-radiation Drugs Market Outlook 2031

  • The industry was valued at US$ 3.4 Bn in 2021
  • It is projected to grow at a CAGR of 9.9% from 2022 to 2031 to reach more than US$ 9.6 Bn by the end of 2031

Analysts’ Viewpoint

High prevalence of cancer and Acute Radiation Syndrome (ARS) is driving the anti-radiation drugs business. Potassium iodide (KI), an anti-radiation drug, provides some protection in cases of radiation exposure. Rise in concerns regarding the usage of nuclear weapons in wars is expected to augment the demand for anti-radiation pills. Detonation of a nuclear weapon may lead to the release of radioactive iodine.

Biotechnology firms are getting government contracts to develop drugs for the treatment of ARS. Vendors in the anti-radiation drugs sector are investing significantly in expansion of their production capabilities. They are also launching new products to broaden their anti-radiation drugs market share.

Anti Radiation Drugs Market

Market Introduction

Anti-radiation drugs offer protection against radiation exposure. These drugs include KI, Prussian Blue, and DTPA (Diethylenetriamine pentaacetate). Anti-radiation medicines help block the absorption and subsequent concentration of radioactive iodine in the thyroid gland. KI must be consumed before or shortly after exposure to radioactive iodine for better results. It is effective only against radioactive iodine and not against other types of radiation. Oxidation of ferrous ferrocyanide salts produces Prussian blue that is used for the treatment of thallium poisoning or radioactive cesium poisoning.

Request a sample to get extensive insights into the Anti-radiation Drugs Market

Increase in Risk of Radiological and Nuclear Incidents Augmenting Anti-radiation Drugs Market Size

Radiological preparedness and development of radiation countermeasures have become critical owing to the surge in risk of radiological and nuclear accidents or terrorist attacks. These measures are fueling the radiation detection, monitoring, and safety market. Radiation countermeasures include compounds that can potentially counteract the effects of either accidental or deliberate radiation exposure (e.g., nuclear reactor meltdown, dirty bomb, or nuclear bomb explosion).

The U.S. recently invested US$ 290 Mn on anti-radiation pills to "save lives following radiation and nuclear emergencies." In October 2022, the U.S. Department of Health and Human Services (HHS) announced the purchase of the drug Nplate from Amgen USA Inc. as part of a "long-standing program" of emergency preparedness using authority and funds authorized by the Project Bioshield Act of 2004. According to the HHS, Nplate is intended for the treatment of patients with ARS, which occurs when a person's entire body is exposed to a high dose of penetrating radiation. Thus, rise in investment in radiation countermeasures is fueling the anti-radiation drugs market.

Rise in R&D of Radiopharmaceuticals

Various studies are currently focusing on the development of radiopharmaceuticals, a new class of drugs that delivers radiation therapy directly and specifically to cancer cells. Over the last few years, there has been a surge in research and clinical trials involving new radiopharmaceuticals. Radiopharmaceuticals are being developed and tested for a variety of cancers, including melanoma, lung cancer, colorectal cancer, and leukemia.

Radioprotectors are compounds used to protect against radiation injury. They are usually administered prior to radiation exposure. Mitigators can protect against radiation injury when given after exposure but before symptoms appear. Radioprotectors and mitigators have the potential to improve outcomes of radiotherapy in cancer treatment by allowing higher doses of radiation and/or reducing damage to normal tissues. Thus, R&D in radioprotectors and mitigators is anticipated to fuel market expansion during the forecast period.

Request a custom report on Anti-radiation Drugs Market

High Demand for Potassium Iodide in Anti-radiation Drugs Market

In terms of compound, the Potassium Iodide (KI) segment held significant share of the industry in 2021. KI tablets offer some protection in cases of radiation exposure. They contain non-radioactive iodine and can aid in blocking the radioactive iodine absorption and subsequent concentration in the thyroid gland. The active ingredient, KI, is a highly soluble form of iodine that the body absorbs and stores in the thyroid gland. This saturates the gland, filling it to capacity. Thus, the body rejects and excretes the radioactive form when exposed to radioactive iodine.

KI has been tested numerous times, both in the lab and during the Chernobyl disaster. The U.S. Nuclear Regulatory Commission (NRC) documented its safety and effectiveness, noting that children exposed to radiation at Chernobyl were much safer if given KI. Some radiological emergencies may cause large amounts of radioiodine to be released into the environment. Inhaling or ingesting radioiodine-contaminated food can cause thyroid radiation injury, due to the accumulation of iodine in the thyroid gland.

Growth in Prevalence of Acute Radiation Syndrome

According to the latest anti-radiation drugs market trends, the Acute Radiation Syndrome (ARS) application segment accounted for the largest share of the global anti-radiation drugs business in 2021. ARS is one of the most challenging aspects of public health and medical response to a nuclear or radiological incident.

ARS is a group of syndromes that develops after short-term whole-body exposure to ionizing radiation at doses greater than 0.7-1.0 Gy. Bone marrow syndrome, gastrointestinal syndrome, cardiovascular syndrome, central nervous system (or neurological) syndrome, and cutaneous (skin) syndrome are the most common syndromes.

Bone marrow syndrome is a common cause of death due to the destruction of bone marrow, which causes infections and hemorrhage. Protein-based medications such as filgrastim (Neupogen), sargramostim (Leukine), and pegfilgrastim (Neulasta) may increase white blood cell production and aid in the prevention of subsequent infections.

Surge in Number of Hospital Pharmacies

In terms of distribution channel, the hospital pharmacies segment is projected to account for major share of the industry during the forecast period. Growth of the segment can be ascribed to rise in the burden of cancer worldwide. Additionally, increase in healthcare expenditure in developing and developed economies and surge in the number of cancer specialty hospitals are driving the segment.

The retail pharmacies segment is expected to grow at a significant rate during the forecast period due to the approval and launch of new drugs. In May 2016, the FDA approved an abbreviated new drug application from Mission Pharmacal Company for over-the-counter liquid potassium iodide oral solution USP. Anti-radiation medication is intended for the prevention of thyroid cancer in the event of a nuclear emergency.

Regional Outlook of Global Anti-radiation Drugs Market

North America is projected to dominate the global business during the forecast period. Market progress in the region can be ascribed to the increase in number of radiation facilities and rise in investment in the anti-radiation devices market. The U.S. Government has been instrumental in the development of drugs and biologics as Medical Countermeasures (MCMs) for ARS and Delayed Effects of Acute Radiation Exposure (DEARE).

The MCM program focuses on the development of drugs approved by the FDA for usage as radiation injury mitigators following a nuclear detonation. The National Cancer Institute (NCI) is engaged in enhancing these R&D efforts and investments to explore their potential usage for cancer treatment. Thus, increase in R&D of anti-radiation drugs is anticipated to propel market statistics in North America.

Analysis of Key Players

The market for anti-radiation drugs is consolidated, with the presence of a small number of leading players. Expansion of product portfolio and mergers & acquisitions are key strategies implemented by prominent manufacturers. Amgen Inc., Anbex Inc., Arco Pharmaceuticals LLC, BTG International Inc., Cellphire, Inc., Chrysalis BioTherapeutics, Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Myelo Therapeutics GmbH, Partner Therapeutics, and Pluri Inc. are major entities operating in the market.

Key Developments

  • In August 2022, the European Union announced plans to distribute 5.5 million potassium iodide tablets to residents living near the Zaporizhzhia nuclear power plant in Ukraine
  • In May 2022, Darnitsa produced over 6.7 million doses of the anti-radiation drug Potassium Iodide-125-Darnitsa. The drug was developed in accordance with iodine prophylaxis regulations in the event of a radiation accident.

The market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 3.4 Bn

Market Forecast Value in 2031

More than US$ 9.6 Bn

Growth Rate

(CAGR)

9.9%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis and regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Compound
    • Potassium Iodide (KI)
    • Prussian Blue
    • DTPA (Diethylenetriamine Pentaacetate)
    • Others
  • Application
    • Acute Radiation Syndrome (ARS)
    • Cancer Treatment
    • Radiation Exposure
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Amgen Inc.  
  • Anbex Inc.
  • Arco Pharmaceuticals LLC
  • BTG International Inc.
  • Cellphire, Inc.
  • Chrysalis BioTherapeutics, Inc.
  • Darnitsa
  • Enzychem Lifesciences Corporation
  • Humanetics Corporation
  • Mission Pharmacal Company
  • Myelo Therapeutics GmbH
  • Partner Therapeutics
  • Pluri Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Anti-radiation Drugs Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global anti-radiation drugs market in 2021?

It was valued at US$ 3.4 Bn in 2021

How big will the industry be in 2031?

It is projected to reach more than US$ 9.6 Bn by 2031

What will be the CAGR during the forecast period (2022–2031)?

The business is anticipated to grow at a CAGR of 9.9% from 2022 to 2031

Which are the prominent trends that affect market growth?

Increase in prevalence of cancer and rise in number of radiation therapies

Which region will account for major share during the forecast period?

North America is expected to account for major share during the forecast period

Who are the prominent players in the global anti-radiation drugs sector?

Amgen Inc., Anbex Inc., Arco Pharmaceuticals LLC, BTG International Inc., Cellphire, Inc., Chrysalis BioTherapeutics, Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Myelo Therapeutics GmbH, Partner Therapeutics, and Pluri Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anti-radiation Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Anti-radiation Drugs Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Industry Events (Partnership, Investment, Merger & Acquisition, etc.)

    5.3. Insights on Radiation Pills

    5.4. Regulatory Scenario, by Key Region/ Country

    5.5. COVID-19 Impact Analysis

6. Global Anti-radiation Drugs Market Analysis and Forecast, by Compound

    6.1. Introduction & Definition

    6.2. Market Value Forecast, by Compound, 2017–2031

        6.2.1. Potassium Iodide (KI)

        6.2.2. Prussian Blue

        6.2.3. DTPA (Diethylenetriamine Pentaacetate)

        6.2.4. Others

    6.3. Market Attractiveness, by Compound

7. Global Anti-radiation Drugs Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Market Value Forecast, by Application, 2017–2031

        7.2.1. Acute Radiation Syndrome (ARS)

        7.2.2. Cancer Treatment

        7.2.3. Radiation Exposure

        7.2.4. Others

    7.3. Market Attractiveness Analysis, by Application

8. Global Anti-radiation Drugs Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Market Value Forecast, by Distribution Channel, 2017–2031

        8.2.1. Hospital Pharmacies

        8.2.2. Retail Pharmacies

        8.2.3. Others

    8.3. Market Attractiveness Analysis, by Distribution Channel

9. Global Anti-radiation Drugs Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Anti-radiation Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Compound, 2017–2031

        10.2.1. Potassium Iodide (KI)

        10.2.2. Prussian Blue

        10.2.3. DTPA (Diethylenetriamine Pentaacetate)

        10.2.4. Others

    10.3. Market Value Forecast, by Application, 2017–2031

        10.3.1. Acute Radiation Syndrome (ARS)

        10.3.2. Cancer Treatment

        10.3.3. Radiation Exposure

        10.3.4. Others

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Compound

        10.6.2. By Application

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Anti-radiation Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Compound, 2017–2031

        11.2.1. Potassium Iodide (KI)

        11.2.2. Prussian Blue

        11.2.3. DTPA (Diethylenetriamine Pentaacetate)

        11.2.4. Others

    11.3. Market Value Forecast, by Application, 2017–2031

        11.3.1. Acute Radiation Syndrome (ARS)

        11.3.2. Cancer Treatment

        11.3.3. Radiation Exposure

        11.3.4. Others

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Compound

        11.6.2. By Application

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Anti-radiation Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Compound, 2017–2031

        12.2.1. Potassium Iodide (KI)

        12.2.2. Prussian Blue

        12.2.3. DTPA (Diethylenetriamine Pentaacetate)

        12.2.4. Others

    12.3. Market Value Forecast, by Application, 2017–2031

        12.3.1. Acute Radiation Syndrome (ARS)

        12.3.2. Cancer Treatment

        12.3.3. Radiation Exposure

        12.3.4. Others

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Compound

        12.6.2. By Application

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Anti-radiation Drugs Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Compound, 2017–2031

        13.2.1. Potassium Iodide (KI)

        13.2.2. Prussian Blue

        13.2.3. DTPA (Diethylenetriamine Pentaacetate)

        13.2.4. Others

    13.3. Market Value Forecast, by Application, 2017–2031

        13.3.1. Acute Radiation Syndrome (ARS)

        13.3.2. Cancer Treatment

        13.3.3. Radiation Exposure

        13.3.4. Others

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Compound

        13.6.2. By Application

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Anti-radiation Drugs Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Compound, 2017–2031

        14.2.1. Potassium Iodide (KI)

        14.2.2. Prussian Blue

        14.2.3. DTPA (Diethylenetriamine Pentaacetate)

        14.2.4. Others

    14.3. Market Value Forecast, by Application, 2017–2031

        14.3.1. Acute Radiation Syndrome (ARS)

        14.3.2. Cancer Treatment

        14.3.3. Radiation Exposure

        14.3.4. Others

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Others

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Compound

        14.6.2. By Application

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competitive Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company (2021)

    15.3. Company Profiles

        15.3.1. Amgen Inc.

            15.3.1.1. Company Overview

            15.3.1.2. Compound Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Financial Overview

            15.3.1.5. Strategic Overview

        15.3.2. Anbex Inc.

            15.3.2.1. Company Overview

            15.3.2.2. Compound Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Financial Overview

            15.3.2.5. Strategic Overview

        15.3.3. Arco Pharmaceuticals LLC

            15.3.3.1. Company Overview

            15.3.3.2. Compound Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Financial Overview

        15.3.4. BTG International Inc.

            15.3.4.1. Company Overview

            15.3.4.2. Compound Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Financial Overview

            15.3.4.5. Strategic Overview

        15.3.5. Cellphire, Inc.

            15.3.5.1. Company Overview

            15.3.5.2. Compound Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Financial Overview

            15.3.5.5. Strategic Overview

        15.3.6. Chrysalis BioTherapeutics, Inc.

            15.3.6.1. Company Overview

            15.3.6.2. Compound Portfolio

            15.3.6.3. SWOT Analysis

        15.3.7. Darnitsa

            15.3.7.1. Company Overview

            15.3.7.2. Compound Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Strategic Overview

        15.3.8. Enzychem Lifesciences Corporation

            15.3.8.1. Company Overview

            15.3.8.2. Compound Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Strategic Overview

        15.3.9. Humanetics Corporation

            15.3.9.1. Company Overview

            15.3.9.2. Compound Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Financial Overview

            15.3.9.5. Strategic Overview

        15.3.10. Mission Pharmacal Company

            15.3.10.1. Company Overview

            15.3.10.2. Compound Portfolio

            15.3.10.3. SWOT Analysis

            15.3.10.4. Financial Overview

            15.3.10.5. Strategic Overview

        15.3.11. Myelo Therapeutics GmbH

            15.3.11.1. Company Overview

            15.3.11.2. Compound Portfolio

            15.3.11.3. SWOT Analysis

            15.3.11.4. Financial Overview

            15.3.11.5. Strategic Overview

        15.3.12. Partner Therapeutics

            15.3.12.1. Company Overview

            15.3.12.2. Compound Portfolio

            15.3.12.3. SWOT Analysis

            15.3.12.4. Financial Overview

            15.3.12.5. Strategic Overview

        15.3.13. Pluri Inc.

            15.3.13.1. Company Overview

            15.3.13.2. Compound Portfolio

            15.3.13.3. SWOT Analysis

            15.3.13.4. Financial Overview

            15.3.13.5. Strategic Overview

        15.3.14. Other Players

            15.3.14.1. Company Overview

            15.3.14.2. Compound Portfolio

            15.3.14.3. SWOT Analysis

            15.3.14.4. Financial Overview

            15.3.14.5. Strategic Overview

List of Tables

Table 01: Global Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017–2031

Table 02: Global Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017–2031

Table 07: North America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 08: North America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017–2031

Table 11: Europe Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 12: Europe Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017–2031

Table 15: Asia Pacific Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 16: Asia Pacific Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017–2031

Table 19: Latin America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 20: Latin America Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Compound, 2017–2031

Table 23: Middle East & Africa Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Middle East & Africa Anti-radiation Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Anti-radiation Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031

Figure 02: Global Anti-radiation Drugs Market Revenue (US$ Mn), by Compound, 2021

Figure 03: Global Anti-radiation Drugs Market Value Share, by Compound, 2021

Figure 04: Global Anti-radiation Drugs Market Revenue (US$ Mn), by Application, 2021

Figure 05: Global Anti-radiation Drugs Market Value Share, by Application, 2021

Figure 06: Global Anti-radiation Drugs Market Revenue (US$ Mn), by Distribution Channel, 2021

Figure 07: Global Anti-radiation Drugs Market Value Share, by Distribution Channel, 2021

Figure 08: Global Anti-radiation Drugs Market Value Share, by Region, 2021

Figure 09: Global Anti-radiation Drugs Market Value (US$ Mn) Forecast, 2017–2031

Figure 10: Global Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031

Figure 11: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Potassium Iodide (KI), 2017–2031

Figure 12: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by DTPA (Diethylenetriamine Pentaacetate), 2017–2031

Figure 13: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prussian Blue, 2017–2031

Figure 14: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031

Figure 15: Global Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022-2031

Figure 16: Global Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031

Figure 17: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Acute Radiation Syndrome (ARS), 2017–2031

Figure 18: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cancer Treatment, 2017–2031

Figure 19: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Radiation Exposure, 2017–2031

Figure 20: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031

Figure 21: Global Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022-2031

Figure 22: Global Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 23: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2031

Figure 24: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2031

Figure 25: Global Anti-radiation Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031

Figure 26: Global Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031

Figure 27: Global Anti-radiation Drugs Market Value Share Analysis, by Region, 2017 and 2031

Figure 28: Global Anti-radiation Drugs Market Attractiveness Analysis, by Region, 2022-2031

Figure 29: North America Anti-radiation Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 30: North America Anti-radiation Drugs Market Attractiveness Analysis, by Country, 2017–2031

Figure 31: North America Anti-radiation Drugs Market Value Share Analysis, by Country, 2017 and 2031

Figure 32: North America Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031

Figure 33: North America Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031

Figure 34: North America Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 35: North America Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022–2031

Figure 36: North America Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022–2031

Figure 37:North America Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 38: Europe Anti-radiation Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 39: Europe Anti-radiation Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 40: Europe Anti-radiation Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 41: Europe Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031

Figure 42: Europe Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031

Figure 43: Europe Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 44: Europe Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022–2031

Figure 45: Europe Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022–2031

Figure 46: Europe Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 47: Asia Pacific Anti-radiation Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 48: Asia Pacific Anti-radiation Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 49: Asia Pacific Anti-radiation Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 50: Asia Pacific Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031

Figure 51: Asia Pacific Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031

Figure 52: Asia Pacific Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 53: Asia Pacific Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022–2031

Figure 54: Asia Pacific Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022–2031

Figure 55: Asia Pacific Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 56: Latin America Anti-radiation Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 57: Latin America Anti-radiation Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 58: Latin America Anti-radiation Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 59: Latin America Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031

Figure 60: Latin America Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031

Figure 61: Latin America Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 62: Latin America Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022–2031

Figure 63: Latin America Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022–2031

Figure 64: Latin America Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 65: Middle East & Africa Anti-radiation Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 66: Middle East & Africa Anti-radiation Drugs Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

Figure 67: Middle East & Africa Anti-radiation Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

Figure 68: Middle East & Africa Anti-radiation Drugs Market Value Share Analysis, by Compound, 2017 and 2031

Figure 69: Middle East & Africa Anti-radiation Drugs Market Value Share Analysis, by Application, 2017 and 2031

Figure 70: Middle East & Africa Anti-radiation Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2031

Figure 71: Middle East & Africa Anti-radiation Drugs Market Attractiveness Analysis, by Compound, 2022–2031

Figure 72: Middle East & Africa Anti-radiation Drugs Market Attractiveness Analysis, by Application, 2022–2031

Figure 73: Middle East & Africa Anti-radiation Drugs Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

938

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved